Ribociclib Interactions
Lisdexamphetamine
No clinically significant drug interactions identified.
Lisinopril
No clinically significant drug interactions identified.
Loperamide
Caution - QT prolongation (EKG monitoring required). Consider choosing an alternative agent.
Lorazepam
No clinically significant drug interactions identified.
Losartan
No clinically significant drug interactions identified.
Medroxyprogesterone
Caution - increased level of medroxyprogesterone due to 3A4 inhibition. Monitor for signs of toxicity. If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Memantine
Caution - increased level of memantine due to OCT2 inhibition. Monitor for signs of toxicity. If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Metformin
Caution - increased level of metformin due to OCT1/OCT2 inhibition. Monitor for signs of toxicity. If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Methadone
Avoid combination - increased level of methadone due to 3A4 inhibition. Also additive risk of QT prolongation. Choose an alternative agent.
Methimazole
No clinically significant drug interactions identified.
Methylphenidate
No clinically significant drug interactions identified.
Metoclopramide
Caution - QT prolongation (EKG monitoring required). Consider choosing an alternative agent.
Metoprolol
No clinically significant drug interactions identified.
Metrondiazole
Caution - QT prolongation (EKG monitoring required). Consider choosing an alternative agent.
Mirtazapine
Caution - QT prolongation (EKG monitoring required). Increased level of mirtazapine due to 3A4 inhibition. Monitor for signs of toxicity. If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Limit dose to 7.5mg-15mg maximum. Consider choosing an alternative agent.
Misoprostol
No clinically significant drug interactions identified.
Montelukast
No clinically significant drug interactions identified.
Morphine
No clinically significant drug interactions identified.
Moxifloxacin
Avoid combination - additive risk of QT prolongation. Choose an alternative agent.
Naltrexone
No clinically significant drug interactions identified.
Naproxen
No clinically significant drug interactions identified.
Nifedipine ER
Caution - increased level of nifedipine due to 3A4 inhibition. Monitor for signs of toxicity (hypotension). If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Nitrofurantoin
No clinically significant drug interactions identified.
Nortriptyline
Caution - QT prolongation (EKG monitoring required). Consider choosing an alternative agent.
Olanzapine
Caution - QT prolongation (EKG monitoring required). Consider choosing an alternative agent.
Omeprazole
No clinically significant drug interactions identified.
Ondansetron
Caution - QT prolongation (EKG monitoring required). Use lowest effective dose for shortest duration clinically indicated. Avoid IV route of administration. Consider choosing an alternative agent.
Orlistat
No clinically significant drug interactions identified.
Oxazepam
No clinically significant drug interactions identified.
Oxybutynin
No clinically significant drug interactions identified.
Oxycodone
Caution - increased level of oxycodone due to 3A4 inhibition. Monitor for signs of toxicity (sedation, confusion, dizziness). If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Pantoprazole
No clinically significant drug interactions identified.
Paroxetine
Caution - QT prolongation (EKG monitoring required). Consider choosing an alternative agent.
Penicillin V
No clinically significant drug interactions identified.
Perindopril
No clinically significant drug interactions identified.
Phenobarbital
Avoid combination - decreased level of ribociclib due to 3A4 induction. Choose an alternative agent.
Phenytoin
Avoid combination - decreased level of ribociclib due to 3A4 induction. Choose an alternative agent.
Pioglitazone
No clinically significant drug interactions identified.
Pravastatin
No clinically significant drug interactions identified.
Prazosin
No clinically significant drug interactions identified.
Prednisone
Caution - increased level of prednisone due to 3A4 inhibition. Monitor for signs of toxicity. If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Pregabalin
No clinically significant drug interactions identified.
Prochlorperazine
No clinically significant drug interactions identified.
Propranolol
No clinically significant drug interactions identified.
Quetiapine
Avoid combination - increased level of quetiapine due to 3A4 inhibition. Also additive risk of QT prolongation. Choose an alternative agent.
Rabeprazole
No clinically significant drug interactions identified.
Ramipril
No clinically significant drug interactions identified.
Ranitidine
No clinically significant drug interactions identified.
Repaglinide
Caution - increased level of repaglinide due to 3A4 inhibition. Monitor for signs of toxicity. If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Risedronate
No clinically significant drug interactions identified.
Risperidone
Caution - QT prolongation (EKG monitoring required). Increased level of risperidone due to 3A4 inhibition. Monitor for signs of toxicity. If initiating therapy, titrate slowly. If already established on therapy, may require dose advised. Consider choosing an alternative agent.
Rivaroxaban
Caution - increased level of rivaroxaban due to 3A4 inhibition. Monitor for signs of bleeding - dose reduction may be required. Consider choosing an alternative agent.
Rivastigmine
Caution - QT prolongation (EKG monitoring required). Consider choosing an alternative agent.
Rizatriptan
No clinically significant drug interactions identified.
Ropinirole
No clinically significant drug interactions identified.
Rosuvastatin
Caution - increased level of rosuvastatin due to 3A4 inhibition. Monitor for signs of toxicity. If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Sacubitril/Valsartan (Entresto)
No clinically significant drug interactions identified.
Saxagliptin
Caution - increased level of saxagliptin due to 3A4 inhibition. Monitor for signs of toxicity. If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Limit dose to 2.5mg/day maximum. Consider choosing an alternative agent.
Semaglutide
No clinically significant drug interactions identified.
Sennosides
No clinically significant drug interactions identified.
Sertraline
Caution - QT prolongation (EKG monitoring required). Increased level of sertraline due to 3A4 inhibition. Monitor for signs of toxicity. If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Sildenafil
Caution - increased level of sildenafil due to 3A4 inhibition. Monitor for signs of toxicity. If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Simvastatin
Caution - increased level of simvastatin due to 3A4 inhibition. Monitor for signs of toxicity. If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Sitagliptin
No clinically significant drug interactions identified.
Solifenacin
Caution - QT prolongation (EKG monitoring required). Increased level of solifenacin due to 3A4 inhibition. Monitor for signs of toxicity. If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Spironolactone
No clinically significant drug interactions identified.
Sulfamethoxazole/ trimethoprim
No clinically significant drug interactions identified.
Sumitriptan
No clinically significant drug interactions identified.
Tadalafil
Caution - increased level of tadalafil due to 3A4 inhibition. Monitor for signs of toxicity. If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Tamsulosin
Caution - increased level of tamsulosin due to 3A4 inhibition. Monitor for signs of toxicity (hypotension). Consider choosing an alternative agent.
Telmisartan
No clinically significant drug interactions identified.
Temazepam
No clinically significant drug interactions identified.
Ticagrelor
Caution - increased level of ticagrelor due to 3A4 inhibition. Monitor for signs of bleeding. Consider choosing an alternative agent.
Trazodone
Avoid combination - increased level of trazodone due to 3A4 inhibition. Also additive risk of QT prolongation. Choose an alternative agent.
Venlafaxine
Caution - QT prolongation (EKG monitoring required). Consider choosing an alternative agent.
Verapamil
Avoid combination - increased level of both agents due to 3A4 inhibition. Choose an alternative agent.
Zopiclone
Caution - increased level of zopiclone due to 3A4 inhibition. Monitor for signs of toxicity (sedation). If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
